Experts examine access and cost issues of GI drugs

A shift has occurred in the treatment costs of inflammatory bowel disease and other GI conditions. Historically, the highest costs associated with treatment were related to hospitalizations. Today, much of the cost can be attributed to the increased expense of prescription drugs, said Akbar K. Waljee, MD, one of four speakers to discuss the cost and cost-effectiveness of various GI drugs during an AGA symposium at DDW 2016.

GIs face evolving ethical, clinical challenges of genetic testing

While the advent of next-generation, high-throughput genetic sequencing is propelling genomic science forward, it has also created ethical and medical challenges for gastroenterologists, according to C. Richard Boland, MD, AGAF, one of three medical professionals to discuss these pitfalls during an AGA symposium Sunday afternoon at Digestive Disease Week®.